Extensive in vitro and, to a more limited extent, animal research have demonstrated the health potential of a wide set of egg protein hydrolysates; however, well-designed human intervention studies are scarce. Health claim assessment, however, sets high standards for characterisation of the bioactive peptides, investigation of the mode-of-action and convincing human intervention studies. In this review, we discuss the state-of-the-art and knowledge gaps related to egg-derived peptide bioavailability and bioactivity. In addition, we will formulate recommendations for appropriate design of future human intervention trials with egg-derived peptides.